Delta, Kelowna, BC – March 18, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,
www.potcasts.ca
release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts #542, Cannabis News and Stocks on the Move; (TSX: APHA) (Nasdaq: APHA), (OTCQB: ALID) (TSXV: KHRN) (OTCQX: KHRNF)
SHARE PODCAST:
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Aphria Inc. (
TSX: APHA
) (
Nasdaq: APHA
), a leading global cannabis-lifestyle consumer packaged goods company, and Tilray, Inc. (
Nasdaq: TLRY
), a global pioneer in cannabis research, cultivation, production and distribution,
announced that
:
- Aphria has obtained an interim order of the Ontario Superior Court of Justice in connection with its proposed business combination with Tilray pursuant to an arrangement to be implemented under a statutory plan of arrangement pursuant to section 182 of the Business Corporations Act (Ontario);
- They have received the required regulatory approvals necessary to complete the proposed business combination between the two companies;
- They have filed their joint proxy statement/management information circular and related materials in respect of the special meeting of Aphria shareholders to be held on April 14, 2021 and the special meeting of the holders of the Tilray class 2 common stock to be held on April 16, 2021, to approve the resolutions necessary to implement the Arrangement; and
- The record date for determining the Aphria Shareholders and the Tilray Stockholders entitled to receive notice of and vote at the Aphria Meeting and the Tilray Meeting, respectively, was fixed by each of Aphria and Tilray to be the close of business on March 12, 2021.
Irwin D. Simon, Aphria’s Chairman and Chief Executive Officer, who will have these same roles with the Combined Company, commented, “We are excited to advance closer towards the completion of our complementary and highly scalable strategic transaction with Tilray. On behalf of our board of directors, we recommend Aphria Shareholders vote “FOR” the resolution required to approve the business combination with Tilray. We continue to believe our combined business strengths and capabilities will help us to connect more effectively with new and existing consumers and patients across Canada and internationally. Together, we expect the Combined Company to have a strong financial profile, low-cost production, leading brands, distribution network and unique partnerships, positioning us to deliver sustainable value for all stakeholders.”
Mr. Simon, concluded, “We continue to maintain our financial flexibility through the strength of our balance sheet and access to capital. As a Combined Company, we expect to continue to pursue M&A in the U.S. across the branded consumer products industry that are accretive and can parlay into complementary cannabis products when we are able to do so.”
At the Aphria Meeting, Aphria Shareholders will be asked to consider and pass a special resolution, approving the Arrangement. The Aphria Resolution must be approved by at least 66⅔% of the votes cast at the Aphria Meeting by the Aphria Shareholders, virtually present or represented by proxy at the Aphria Meeting. Aphria Shareholders must vote their proxies before 4:00 p.m. (Eastern time) on April 12, 2021.
Allied Corp. (
OTCQB: ALID
), an international medical cannabis company focused on creating and providing targeted psilocybin and cannabinoid health solutions to address today’s medical issues,
announced
that it has submitted a provisional patent for the Allied therapeutic formulation and treatment regimen involving a prescription drug followed by a prophylactic daily drug formulation. These two products together administered under a novel treatment regimen is intended to be tested through the Allied clinical trial infrastructure to seek a drug indication for general depression and anxiety.
The provisional patent submitted is entitled: COMPOSITIONS AND FORMULATIONS OF PSILOCYBIN AND CANNABINOIDS AND METHODS OF THEIR USE TOGETHER FOR TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH.
This provisional patent contemplates the full scope treatment of general depression and anxiety with a proprietary Rx prescription medication followed by a daily prophylactic dose of proprietary medicinal compositions. This includes a proprietary dosing and therapeutic regimen of psilocybin, additional functional mushrooms and cannabinoid therapeutics.
Among the various aspects of the present invention contemplated in the provisional patent submission are compositions, formulations, methods for modulating endocannabinoid system activity, for modulating neuro-steroid biosynthesis, and for modulating neurotransmission, and methods for treating mental health disorders and improving mental health, using synergistic combinations of psilocybin, cannabinoids, and other active agents, provided in distinct daily dosing regimens.
The content contemplated in the provisional patent submission describes the real world pharmaceutical formulations that Allied intends to research via human clinical trials in order to seek a drug indication.
“This further deepens our product pipeline beyond our current products under provisional patent. We are excited to put our best physicians and scientists to work to prove the efficacy of this novel therapeutic approach to full scope treatment of mental health conditions,” says Calum Hughes, CEO of Allied. “Currently, treatment options for mental health disorders consist generally of psychotherapy, pharmacotherapy, and direct brain intervention. We at Allied aim to develop an additional evidence-informed treatment option that physicians will be able to prescribe to the people who most need it.”
Khiron Life Sciences Corp. (
TSXV: KHRN
) (
OTCQX: KHRNF
), a vertically integrated cannabis leader with core operations in Latin America and Europe,
today announced
that it has opened two additional satellite Zerenia clinics in Colombia following the success of its initial small format clinic in Medellin. In line with the Company’s stated strategy, the new satellite clinics in Cali and Bucaramanga opened their doors to patients in early March, 2021. The satellite clinics are located in high-traffic, medical-hub neighbourhoods and are supported by Khiron’s flagship health centres in Bogota.
The new Zerenia locations expand Khiron’s clinic network to six, improving access to the Company’s clinic services and medical cannabis products for patients across the country. Patients in Cali and Bucaramanga may now connect with medical specialists trained in the ethical, safe, and responsible prescription of cannabis-based medications in person or through Khiron’s Doctor Zerenia telemedicine platform.
“We are off to a great start in 2021 and the Zerenia satellite clinic model is proving to be an exceptional platform for reaching new patients. The rapid expansion of clinics is helping Khiron reach more patients in more places, more conveniently, in these cities. With the opening of two new satellite clinics in Cali and Bucaramanga, Khiron has taken another step toward increasing patient access to medical cannabis, with the objective of improving the quality of life for thousands of people in Colombia. Our unique and proven business model will support our goal of reaching 1,000,000 patients by 2024 in a sustainable manner,” comments Alvaro Torres, Khiron CEO and Director.
Based on positive physician and patient feedback at Khiron’s initial satellite clinics, the Company now plans to expand its clinic presence in major metropolitan centres throughout Colombia. Three additional satellite Zerenia clinics, which will focus on treating pathologies such as chronic pain, anxiety, insomnia, depression, headache, epilepsy, and Parkinson’s Disease, are expected to open over the course of the year.
Ikänik Farms
announced
that the Company has received conditional approval from the Canadian Securities Exchange to list the shares of the Company for trading on the CSE, under the ticker symbol “IKNK”, following the completion of its previously announced transaction with Canadian Imperial Venture Corp. (TSXV:CQV.H).
“We are very excited for the future of Ikänik, as we transition to a public company and continue executing on our multi-national objectives.” said Brian Baca, CEO of Ikänik Farms, Inc.
The Company previously announced that it had entered into a business combination agreement with CIVC whereby the Company has agreed to sell all of the issued and outstanding securities of Ikänik Farms and the business of Ikänik Farms by way of a three-cornered amalgamation. The Transaction will result in a reverse takeover of the CIVC by the security holders of Ikänik Farms.
“We are proud to open our company to the world.” said Borja Sanz de Madrid, President of Ikänik Farms International, Inc.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at
https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our
list of top stock trading apps
including Robinhood , Acorn, Stash and others.
To hear more Investorideas.com podcasts visit:
https://www.investorideas.com/Audio/
.
The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Play Music and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com – News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles,
podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns:
Crypto Corner
,
Play by Play
sports and stock news column,
Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast and column,
Cleantech and Climate Change
,
Exploring Mining
the
AI Eye
.
Disclaimer/Disclosure:
Investorideas.com
is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific questions.
More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and our other news services on the Investorideas.com newswire
https://www.investorideas.com/News-Upload/
and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
https://www.facebook.com/Investorideaspotcasts/
https://www.instagram.com/investorideas_potcast/
Download our
Mobile App
for iPhone and Android
Contact Investorideas.com
800-665-0411
